Best Peptides for Fat Loss & Body Recomposition
Fat-targeting peptides researched for lipolysis, metabolic enhancement, and body recomposition beyond weight loss.
Understanding Fat Loss Peptides
Fat loss peptides differ from general weight loss peptides by specifically targeting fat metabolism rather than overall appetite suppression. AOD-9604 is a fragment of growth hormone that promotes lipolysis without the growth-promoting effects. Tesamorelin is FDA-approved for reducing abdominal fat in HIV-associated lipodystrophy. SLU-PP-332 is a novel exercise mimetic that shifts fuel utilization toward fat oxidation. GH secretagogues support body recomposition by promoting fat loss while preserving lean mass.
Key Considerations
- Tesamorelin is the only FDA-approved peptide specifically for fat reduction
- AOD-9604 is popular but has limited human clinical data
- SLU-PP-332 is a small molecule, not technically a peptide
- Fat loss peptides work best with caloric deficit and exercise
- Spot reduction of fat is not supported by science — effects are systemic
FDA Approved Options (3)
Tesamorelin
Also: Egrifta, Egrifta WR, Egrifta SV
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Tirzepatide
Also: Mounjaro, Zepbound, LY3298176
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Setmelanotide
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Research Peptides (12)
These peptides are being researched but are not FDA approved. They should only be considered for research purposes or under medical supervision.
SLU-PP-332
PreclinicalA synthetic small molecule developed at Saint Louis University that activates estrogen-related receptors (ERRs), mimicking the metabolic effects of aerobic exercise. Technically not a peptide but a small organic molecule (MW 290.32), widely discussed in the peptide community as an "exercise mimetic" that boosts fat oxidation, endurance, and mitochondrial function without stimulant effects.
AOD-9604
Clinical TrialsA modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
HGH Fragment 176-191
Clinical TrialsThe lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
5-Amino-1MQ
PreclinicalA selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Survodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
CJC-1295
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
MOTS-c
PreclinicalA mitochondria-derived peptide that regulates metabolic homeostasis. Discovered in 2015, it is being studied for its effects on insulin sensitivity, exercise capacity, and aging.
Humanin
PreclinicalA mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity. Being studied for aging and metabolic benefits.
NAD+ Precursors
Clinical TrialsWhile not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
Cortagen
PreclinicalA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support. Regulates neurotrophic signaling and synaptic stability.
Thyreogen
PreclinicalA peptide bioregulator derived from thyroid tissue. Regulates thyroid function and metabolism. Contains peptide complex with glutamic acid, aspartic acid, tyrosine, phenylalanine, proline, and serine.
Frequently Asked Questions
What peptides target fat specifically?
AOD-9604 (a growth hormone fragment) promotes lipolysis without GH's growth effects. Tesamorelin is FDA-approved for abdominal fat reduction. SLU-PP-332 increases fat oxidation by mimicking exercise metabolism. Fragment 176-191 is similar to AOD-9604.
How is fat loss different from weight loss peptides?
Weight loss peptides like Semaglutide reduce overall appetite and food intake. Fat loss peptides specifically target fat metabolism — promoting lipolysis (fat breakdown) and fatty acid oxidation while potentially preserving muscle mass. The distinction matters for body recomposition goals.
Is AOD-9604 effective for fat loss?
AOD-9604 showed promise in early clinical trials with modest fat reduction, but subsequent larger trials produced mixed results. It was not approved by the FDA. Community use continues with generally positive anecdotal reports, but clinical evidence is limited.
Explore Other Goals
Compare Peptides Side-by-Side
Use our comparison tool to evaluate multiple peptides at once.
Looking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Get Weekly Peptide Research Updates
New peptides, studies, and FDA changes delivered to your inbox.